Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

RF Pollock; S Heller; Thomas Pieber; V Woo; J Gundgaard; N Hallén; M Luckevich; D Tutkunkardas; B Zinman; DEVOTE Study Group

doi:10.1111/dom.13730

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

RF Pollock
, S Heller
, Thomas Pieber
, V Woo
, J Gundgaard
, N Hallén
, M Luckevich
, D Tutkunkardas
, B Zinman
, DEVOTE Study Group

Klinische Abteilung für Endokrinologie und Diabetologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit

4 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	Diabetes, Obesity and Metabolism
DOIs	https://doi.org/10.1111/dom.13730
Publikationsstatus	Veröffentlicht - 2019

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

301 Medizinisch-theoretische Wissenschaften, Pharmazie
302 Klinische Medizin
305 Andere Humanmedizin, Gesundheitswissenschaften

Forschungsfelder

Nachhaltige Gesundheitsforschung

Zugriff auf Dokument

10.1111/dom.13730

Andere Dateien und Links

Dieses zitieren

Pollock, RF., Heller, S., Pieber, T., Woo, V., Gundgaard, J., Hallén, N., Luckevich, M., Tutkunkardas, D., Zinman, B., & DEVOTE Study Group (2019). Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13730

@article{9449630902bd444daad1ebc787b73e39,

title = "Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).",

author = "RF Pollock and S Heller and Thomas Pieber and V Woo and J Gundgaard and N Hall{\'e}n and M Luckevich and D Tutkunkardas and B Zinman and \{DEVOTE Study Group\}",

year = "2019",

doi = "10.1111/dom.13730",

language = "English",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "John Wiley and Sons Inc",

}

Pollock, RF, Heller, S, Pieber, T, Woo, V, Gundgaard, J, Hallén, N, Luckevich, M, Tutkunkardas, D, Zinman, B & DEVOTE Study Group 2019, 'Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).', Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13730

TY - JOUR

T1 - Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).

AU - Pollock, RF

AU - Heller, S

AU - Pieber, Thomas

AU - Woo, V

AU - Gundgaard, J

AU - Hallén, N

AU - Luckevich, M

AU - Tutkunkardas, D

AU - Zinman, B

AU - DEVOTE Study Group

PY - 2019

Y1 - 2019

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000471714900021

UR - https://pubmed.ncbi.nlm.nih.gov/30924579

UR - https://pmc.ncbi.nlm.nih.gov/articles/PMC6618053

U2 - 10.1111/dom.13730

DO - 10.1111/dom.13730

M3 - Research article

C2 - 30924579

SN - 1462-8902

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

ER -